FDA warned Arizona clinic Innate Healthcare Institute for selling unapproved umbilical cord stem cells marketed to treat autism.
What happened
FDA reviewed the company's website (last visited August 2025) and found it advertised "umbilical cord mesenchymal stem cells (UC-MSCs)" as a treatment for autism and a long list of other conditions. No inspection was reported; the finding came from the website review. FDA said the product is a drug and a biological product with no approved license, and that it does not qualify for the lighter HCT/P rules (HCT/P means human cells, tissues, or cellular products).
What FDA found
The company markets its stem cell product to treat autism and many other diseases, which makes it a drug and biological product, but it has no approved license (BLA) to sell it.
Section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1); section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1)Processing the umbilical cord into an injectable form changes its original physical structure, so it counts as more than minimal manipulation and loses the lighter HCT/P status.
21 CFR 1271.10(a)(1); 21 CFR 1271.3(f)(1)The product is not meant to do the same basic job in the patient as the cord does in the donor, because it is intended to treat autism rather than act as a conduit.
21 CFR 1271.10(a)(2); 21 CFR 1271.3(c)The product does not carry adequate directions for use, so it is misbranded.
Section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1); 21 CFR 201.5Holding misbranded product for sale after it has moved in interstate commerce is prohibited.
Section 301(k) of the FD&C Act, 21 U.S.C. § 331(k)The company also markets exosomes, which FDA treats as drugs and biological products needing premarket review, and FDA pointed to its safety notice about serious harm in patients given exosome products.
Section 201(g)(1) of the FD&C Act; section 351 of the PHS Act
What FDA wants
FDA tells the company to respond in writing within 15 working days describing the specific steps it has taken or will take, with documents showing the problems are fixed. If the company believes it is not breaking the law, it must send its reasoning and supporting information.
Who should pay attention
- clinics that inject birth-tissue or "stem cell" products
- companies marketing exosome products
- suppliers and distributors of umbilical cord tissue products
This is a summary. Read the original letter on fda.gov.